(Q46598346)

English

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

scientific article published on 12 May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Ralph A. DeFronzo

2

object named as

R A DeFronzo

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

author name string

Y Miyazaki

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

publication date

12 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

1204-1211

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Thiazolidinediones and blood lipids in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Regulation of lipid and lipoprotein metabolism by PPAR activators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00880.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2008.00880.X

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18476983

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46598346&oldid=2121347080"